AMT Stock Recent News

REITs finished the first quarter of 2025 in the red (-3.36%) with a brutal -4.92% average total return in March. Large cap (-2.04%) and mid cap REITs (-2.63%) saw modest losses, but small caps (-4.16%) and micro caps (-16.19%) had a particularly bad month. Only 29.49% of REIT securities had a positive total return in March.

uniQure's AMT-130 gene therapy for Huntington's Disease shows promising trial data, leading to significant stock price increases and potential for FDA accelerated approval. QURE's stock has seen volatility but has near-term catalysts like BLA submission and 36-month trial data, suggesting potential for immediate further gains. Despite competition from PTC518, AMT-130's effectiveness and one-time treatment advantage could drive substantial revenue and stock price growth.

US equity markets steadied this past week while bond markets rallied as investors parsed a surprisingly solid slate of economic data and a decent start to corporate earnings season. Early week gains were pared following comments from Fed Chair Powell regarding the inflationary impact of tariffs and the reluctance of the Fed to step in to support markets. The hawkish comments sparked a series of blistering critiques by President Trump, accusing the Fed Chair of "playing politics" and posting that his "termination cannot come fast enough."

Reflecting on past financial losses, I emphasize the importance of diversification to mitigate risks, as exemplified by my own experience with real estate investments. I advocate for a diversified investment portfolio, including REITs, BDCs, MLPs, Preferreds, Asset Managers, and Dividend Aristocrats, to ensure sustained high cash flow. Highlighting eight high-yielding REITs in the S&P 500, I provide insights into their performance, risks, and growth potential, emphasizing the need for diversification within the REIT sector.

uniQure's AMT-130 gene therapy showed an 80% slowing of Disease progression in Huntington's Disease patients in a phase 1/2 study. Financially strong with $448 million in cash, uniQure can fund operations through H2 2027, reducing immediate financial risk. AMT-191 for Fabry Disease and AMT-162 for ALS are also advancing, diversifying uniQure's pipeline and potential market impact.

REITs are not as heavily impacted by the trade war. Many are strongly outperforming in this environment. I present three safe havens that should thrive, regardless of what happens next with this trade war.

~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~

While macroeconomic headwinds, tariffs, inflation, interest rates, and fears of a recession impact the broad market S&P 500, not all stocks are in the same position.

For more than a century, the stock market has been the premier wealth creator for investors. But this doesn't mean stocks move higher in a straight line.

MarketBeat has many tools, including the Top Rated Dividend Stocks screener. It ranks the top-100 dividend-paying stocks according to analysts' sentiment, giving a 4.00 to those with 100% Buy ratings and a 1.00 to those with 100% Sell ratings.